Document text
Principal Investigator: Matthias Johannes Schnell
Organization: THOMAS JEFFERSON UNIVERSITY
Fiscal Year: 2020
Award: $429,000
Funding agency: National Institute of Allergy and Infectious Diseases
Abstract
The recently emerged coronavirus SARS-CoV-2, the causative agent of COVID-19, is rapidly spreading in the
world with over 4,8 million cases, and 320,000 deaths as of May 16, 2020. This novel coronavirus is thought to
have emerged from a live animal market in Wuhan, China. It has quickly spread in the community with large
clusters of human-to-human transmission. Sequencing of several isolates has determined that the most closely
related strains are SARS-like bat coronavirus lineages. The susceptibility of SARS-CoV-2 to anti-viral
compounds, its ability to replicate in cell lines or host factors regulating its replication are all currently unknown.
Importantly, there are no therapeutics available to treat the virus, although investigational studies are underway.
Modelling of the current outbreak suggests that the virus could infect >1 billion people and become a yearly
epidemic. Identifying people who have developed antibodies is important for the epidemiology as well as patient
care.
With the exponentially expounding threat of SARS-CoV-2 to global health, a vaccine is desperately needed.
Herein we propose the development of a novel, highly efficacious and safe COVID-19 vaccine with facile scale
up potential. Our proposal uses a rabies virus-based vector that has proven to be an efficient vaccine against
emerging and re-emerging infectious diseases. We have demonstrated that inactivated rabies virus particles
containing the coronavirus (CoV) spike S1 protein induce potent immune responses and provide protection in
animal systems against Middle Eastern Respiratory Syndrome coronavirus (MERS) and Severe Acute
Respiratory Syndrome (SARS) coronavirus, both of which are highly related to SARS-CoV-2. A similar vaccine
entitled CoraVax™ is available and herein we propose to analyze CoraVax™ immunogenicity in mice as well as
its abilty to protect in a hamster model.
Terms: <2019 novel coronavirus><2019-nCoV><Adjuvant><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antibody Response><Antigens><Antiviral Agents><Antiviral Drugs><Antivirals><Bats><Biology><COVID-19><COVID-19 vaccine><COVID19><COVID19 vaccine><Cell Line><CellLine><Cessation of life><China><Chiroptera><CoV emergence><Communities><Complementary DNA><Coronaviridae><Coronaviridae Infections><Coronavirus><Coronavirus Infections><Cricetinae><Death><Development><Disease><Disease Outbreaks><Disorder><Emerging Communicable Diseases><Emerging Infectious Diseases><Epidemic><Epidemiology><Goals><Hamsters><Hamsters Mammals><Host Factor><Host Factor Protein><Human><Immune response><Immunity><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><Infection><Integration Host Factors><Investigation><Laboratories><Language><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Mainland China><Mammalia><Mammals><Membrane><Methods><Mice><Mice Mammals><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modeling><Modern Man><Murine><Mus><Outbreaks><Pathogenesis><Pathology><Patient Care><Patient Care Delivery><Predisposition><Proteins><Rabies virus><Recombinant Proteins><Recombinants><Role><SARS><SARS Virus><SARS corona virus><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV disease><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Safety><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe acute respiratory syndrome coronavirus 2><Strains Cell Lines><Susceptibility><System><Testing><Therapeutic><Transmission><Vaccines><Viral><Viral Diseases><Virion><Virus><Virus Diseases><Virus Particle><Virus Replication><Work><Wuhan coronavirus><anti-viral agents><anti-viral drugs><anti-virals><base><cDNA><corona virus><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 vaccine><coronavirus emergence><cultured cell line><develop a vaccine><development of a vaccine><developmental><emergent CoV><emergent coronavirus><emerging CoV><emerging coronavirus><epidemiologic><epidemiological><global health><host response><immunogen><immunogenicity><immunoresponse><membrane structure><model of animal><model organism><mouse model><murine model><nCoV><new CoV><new coronavirus><new vaccines><next generation vaccines><novel><novel CoV><novel coronavirus><novel vaccines><pre-clinical study><preclinical study><response><reverse genetics><scale up><severe acute respiratory syndrome-CoV><social role><transmission process><vaccination strategy><vaccine candidate><vaccine development><vaccine formulation><vector><vector-based vaccine><viral infection><viral multiplication><viral replication><virus infection><virus multiplication><virus-induced disease>